LifeMD, Inc. (NASDAQ:LFMD ) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Justin Schreiber – Chairman and Chief Executive Officer Marc Benathen – Chief Financia
LifeMD, Inc. (LFMD) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.10. This compares to loss of $0.20 per share a year ago.

LifeMD Reports Third Quarter 2024 Results

04:05pm, Thursday, 07'th Nov 2024
Total revenues increased 38% year-over-year to $53.4 million with telehealth revenue up 65% Record gross margin of 90.6%, up 300 basis points from the year-ago period Adjusted EBITDA increased 33% to
LFMD expands its men's health services with TestoRx, offering convenient testosterone therapy and alternative treatments for low testosterone via telehealth.
NEW YORK, Sept. 24, 2024 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, today announced that its Board of Directors has authorized a cash dividen

LifeMD: Selling WorkSimpli Could Be A Catalyst

03:44pm, Tuesday, 10'th Sep 2024
LifeMD's Q2 2024 earnings were mixed, with management failing to monetize the non-core WorkSimpli asset, leading me to assign it no value. Despite management's over-promising, LifeMD's telehealth and
NEW YORK, Aug. 26, 2024 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, today announced that management will be participating in the following inv
LifeMD, Inc. (NASDAQ:LFMD ) Q2 2024 Earnings Conference Call August 7, 2024 4:30 PM ET Company Participants Justin Schreiber – Chairman and Chief Executive Officer Marc Benathen – Chief Financial
LifeMD, Inc. (LFMD) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to loss of $0.23 per share a year ago.

LifeMD Reports Second Quarter 2024 Results

04:05pm, Wednesday, 07'th Aug 2024
Revenue increased 41% year-over-year to $50.7 million with telehealth revenue up 67% Telehealth achieved standalone profitability one quarter ahead of guidance, with adjusted EBITDA of $820,000 Weight
LifeMD is positioned as a high-growth telehealth play with a focus on GLP-1 weight management treatments. The company is guiding for 35% revenue growth in 2024. Its core telehealth business is expecte
Healthcare portfolios include telehealth stocks, notably after the COVID-19 pandemic, which increased global telemedicine usage, demonstrating their importance for lockdowns and other social isolation
NEW YORK, June 25, 2024 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ: LFMD/LFMDP), a leading provider of virtual primary care services, today announced that its Board of Directors has authorized a cash di
NEW YORK, June 10, 2024 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, announces that management will be participating in the Truist Securities H

LifeMD Can Surge on Its GLP-1 Offerings

06:06am, Tuesday, 28'th May 2024
LifeMD Inc. NASDAQ: LFMD is a leading telehealth provider operating an end-to-end virtual healthcare platform. LifeMD operates a direct-to-consumer (DTC) model focused on offering on-demand primary ca
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE